TRICOM: enhanced vaccines as anticancer therapy.
Renewed interest in immune therapies for the treatment of cancer has sparked a number of different immune stimulation approaches. These include antibody based, dendritic cell-based and vaccine-based therapies. The poxvirus-based vaccines incorporating a TRIad of COstimulatory Molecules (TRICOM) will be reviewed here. Through stimulation of cancer-specific T-cell responses, researchers have demonstrated interesting clinical efficacy in addition to the high safety profile in clinical trials.
Levy
Benjamin
B
Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA.
Panicalli
Dennis
D
Marshall
John
J
D019496:Cancer Vaccines / Q000627:therapeutic use*; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D002986:Clinical Trials as Topic; D005822:Genetic Vectors; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
D019496:Cancer Vaccines; D002272:Carcinoembryonic Antigen; D014614:Vaccines, Synthetic; C479602:rF-TRICOM vaccine; C439566:rV-Tricom